AbbVie's oral migraine prevention drug atogepant, already approved in the U.S. under the brand name Qulipta, has now shown it can also tackle one of the trickiest migraine triggers: menstruation. In a late-stage clinical study, the drug successfully met its primary goal of reducing migraine days during the perimenstrual period compared to placebo, averaged across three menstrual cycles.

The study design had patients take atogepant for seven consecutive days, starting three days before the onset of their period — a targeted, cycle-synced approach. Beyond the primary win, the drug also hit key secondary endpoints, showing improvements in headache burden, acute medication use, functional disability, and cognitive function.

By the Numbers:

• 0.8 fewer migraine days on average for atogepant users vs. placebo
• 3 menstrual cycles evaluated in the study
• 7 consecutive days of dosing per cycle, starting 3 days before menses onset

Why it matters: Menstrual migraines are notoriously difficult to manage and affect a significant portion of women who suffer from migraines. A targeted, short-course preventive option could offer a meaningful new tool for clinicians and patients alike.